Published in J Bone Miner Res on February 01, 2011
Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci (2015) 1.25
Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A (2010) 0.99
GNAI1 Suppresses Tumor Cell Migration and Invasion and is Post-Transcriptionally Regulated by Mir-320a/c/d in Hepatocellular Carcinoma. Cancer Biol Med (2012) 0.92
Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res (2013) 0.89
Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family. Br J Pharmacol (2011) 0.88
Cannabinoid receptor type 2 agonist attenuates apoptosis by activation of phosphorylated CREB-Bcl-2 pathway after subarachnoid hemorrhage in rats. Exp Neurol (2014) 0.88
Role of cannabinoids in the regulation of bone remodeling. Front Endocrinol (Lausanne) (2012) 0.80
The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci (2016) 0.79
CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency. Proc Natl Acad Sci U S A (2015) 0.79
Evaluation of common variants in CNR2 gene for bone mineral density and osteoporosis susceptibility in postmenopausal women of Han Chinese. Osteoporos Int (2015) 0.77
Inflammatory Regulation by Driving Microglial M2 Polarization: Neuroprotective Effects of Cannabinoid Receptor-2 Activation in Intracerebral Hemorrhage. Front Immunol (2017) 0.75
A synergistic interaction of 17-β-estradiol with specific cannabinoid receptor type 2 antagonist/inverse agonist on proliferation activity in primary human osteoblasts. Biomed Rep (2015) 0.75
The Influence of the Type of Continuous Exercise Stress Applied during Growth Periods on Bone Metabolism and Osteogenesis. J Bone Metab (2016) 0.75
The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease. Bonekey Rep (2012) 0.75
Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition. Aging Cell (2017) 0.75
Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell (1995) 21.15
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett (1995) 9.62
Mitogen-activated protein kinase pathways. Curr Opin Cell Biol (1997) 9.10
A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell (1994) 8.52
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol (2002) 6.20
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell (2008) 5.93
MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J (1997) 4.39
Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov (2008) 3.93
Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr Opin Cell Biol (1995) 3.79
FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J (1996) 2.98
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol (1995) 2.95
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 2.83
Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J (1995) 2.51
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem (2003) 2.16
Inducible regulatory elements in the human cyclin D1 promoter. Oncogene (1994) 2.16
Cannabinoid receptor signaling. Handb Exp Pharmacol (2005) 2.00
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J Cell Biol (1998) 1.92
Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res (2003) 1.82
Cannabinoid receptors: where they are and what they do. J Neuroendocrinol (2008) 1.63
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med (2005) 1.56
Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene (1998) 1.47
Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J (2009) 1.44
Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res (2007) 1.35
CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol (2007) 1.32
Phosphorylation-independent attenuation of GPCR signalling. Trends Pharmacol Sci (2007) 1.28
Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10. J Biol Chem (2001) 1.20
Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts. J Biol Chem (2004) 1.16
(-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem (1996) 1.15
Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C-dependent. J Biol Chem (2000) 1.11
Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. J Cell Biochem (2004) 1.04
Central IL-1 receptor signaling regulates bone growth and mass. Proc Natl Acad Sci U S A (2005) 1.04
Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology (2008) 1.02
Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol (2008) 1.02
Temporal expression of PDGF receptors and PDGF regulatory effects on osteoblastic cells in mineralizing cultures. Am J Physiol (1997) 1.01
Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol (2006) 1.01
MAP kinase signaling cascades and gene expression in osteoblasts. Front Biosci (1998) 1.00
Mechanical strain and estrogen activate estrogen receptor alpha in bone cells. J Bone Miner Res (2001) 0.96
Kinetic diversity in G-protein-coupled receptor signalling. Biochem J (2007) 0.96
Mitogenic G(i) protein-MAP kinase signaling cascade in MC3T3-E1 osteogenic cells: activation by C-terminal pentapeptide of osteogenic growth peptide [OGP(10-14)] and attenuation of activation by cAMP. J Cell Biochem (2001) 0.91
Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts. Bone (2009) 0.90
Sustained activation of the extracellular signal-regulated kinase pathway is required for extracellular calcium stimulation of human osteoblast proliferation. J Biol Chem (2001) 0.89
Induction of transcriptional activity of the cyclic adenosine monophosphate response element binding protein by parathyroid hormone and epidermal growth factor in osteoblastic cells. J Bone Miner Res (2002) 0.87
ERK1/2-activated de novo Mapkapk2 synthesis is essential for osteogenic growth peptide mitogenic signaling in osteoblastic cells. J Biol Chem (2005) 0.86
Prostaglandin-dependent activation of ERK mediates cell proliferation induced by transforming growth factor beta in mouse osteoblastic cells. Bone (2005) 0.84
Activating MAP KAP kinase 2. Structure (2003) 0.76
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. Cell (2009) 3.63
Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet (2009) 3.59
GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science (2004) 3.38
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 3.02
Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet (2011) 2.71
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis (2009) 2.54
Interaction with vesicle luminal protachykinin regulates surface expression of delta-opioid receptors and opioid analgesia. Cell (2005) 2.52
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci (2002) 2.24
Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest (2013) 2.23
Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A (2003) 2.21
Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One (2008) 2.18
An ancient genome duplication contributed to the abundance of metabolic genes in the moss Physcomitrella patens. BMC Evol Biol (2007) 2.17
A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc Natl Acad Sci U S A (2002) 2.11
Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology (2005) 2.07
Sirt1-deficient mice exhibit an altered cartilage phenotype. Joint Bone Spine (2013) 2.06
Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A (2008) 1.97
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Introducing the German Mouse Clinic: open access platform for standardized phenotyping. Nat Methods (2005) 1.93
Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology (2010) 1.82
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum (2004) 1.67
Mouse closed head injury model induced by a weight-drop device. Nat Protoc (2009) 1.66
A practical note on the use of cytotoxicity assays. Int J Pharm (2004) 1.63
Pharmacology of traumatic brain injury: where is the "golden bullet"? Mol Med (2008) 1.63
Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res Brain Res Rev (2002) 1.61
Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res (2004) 1.59
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol (2010) 1.56
Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proc Natl Acad Sci U S A (2012) 1.56
Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes. Proc Natl Acad Sci U S A (2013) 1.54
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A (2006) 1.52
Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: Implications for treatment of neurological and cognitive deficits. Proc Natl Acad Sci U S A (2004) 1.50
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) (2003) 1.50
A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat Neurosci (2007) 1.49
The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci (2005) 1.47
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci U S A (2008) 1.46
low-level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long-term neurological deficits. J Neurotrauma (2007) 1.45
Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J (2009) 1.44
Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci U S A (2009) 1.44
Mouse phenotyping. Methods (2010) 1.43
A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) (2004) 1.43
Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology (2011) 1.41
Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma (2002) 1.40
Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. Biol Psychiatry (2010) 1.39
Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer (2010) 1.36
Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol (2011) 1.34
Prediction of fracture callus mechanical properties using micro-CT images and voxel-based finite element analysis. Bone (2005) 1.33
Dynamic changes in the recovery after traumatic brain injury in mice: effect of injury severity on T2-weighted MRI abnormalities, and motor and cognitive functions. J Neurotrauma (2008) 1.33
SirT1 enhances survival of human osteoarthritic chondrocytes by repressing protein tyrosine phosphatase 1B and activating the insulin-like growth factor receptor pathway. Arthritis Rheum (2010) 1.33
Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci (2008) 1.32
Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res (2005) 1.32
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol (2007) 1.30
B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol (2004) 1.28
Neuronal 3',3,5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome. J Neurosci (2009) 1.28
Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J (2006) 1.28
Cannabinoids in health and disease. Dialogues Clin Neurosci (2007) 1.28
Cannabinoids and brain injury: therapeutic implications. Trends Mol Med (2002) 1.26
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25
Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol (2008) 1.25
Closed head injury induces upregulation of Beclin 1 at the cortical site of injury. J Neurotrauma (2005) 1.25
CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab (2005) 1.25
A novel regulatory role for stromal-derived factor-1 signaling in bone morphogenic protein-2 osteogenic differentiation of mesenchymal C2C12 cells. J Biol Chem (2007) 1.25
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med (2011) 1.24
Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery (2005) 1.24
Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal. Proc Natl Acad Sci U S A (2002) 1.23
Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J (2009) 1.23
Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A (2006) 1.22
Estrogen receptor-α is required for the osteogenic response to mechanical loading in a ligand-independent manner involving its activation function 1 but not 2. J Bone Miner Res (2013) 1.22
Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res (2011) 1.22
Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther (2002) 1.20
D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J (2007) 1.20
Gene expression profiling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol (2004) 1.20
Vascular endothelial growth factor increases neurogenesis after traumatic brain injury. J Cereb Blood Flow Metab (2010) 1.19
The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis (2005) 1.19
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis (2005) 1.19
The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem (2008) 1.18
A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci (2003) 1.17
Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3beta-dependent and -independent manner. J Biol Chem (2004) 1.16
Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology (2007) 1.15
Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer (2007) 1.15
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine (2008) 1.15
Endocannabinoids and traumatic brain injury. Br J Pharmacol (2011) 1.14
Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice. Ann Rheum Dis (2012) 1.14
Cytotoxicity of nanoparticles independent from oxidative stress. J Toxicol Sci (2009) 1.13
Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet (2005) 1.13